--------------------------------------------------------------------------------
SEC POTENTIAL PERSONS WHO ARE TO RESPOND TO THE COLLECTION OF INFORMATION
1745 (6- CONTAINED IN THIS FORM ARE NOT REQUIRED TO RESPOND UNLESS THE FORM
00) DISPLAYS A CURRENTLY VALID OMB CONTROL NUMBER.
--------------------------------------------------------------------------------
--------------------------
OMB APPROVAL
--------------------------
OMB Number: 3235-0145
--------------------------
UNITED STATES Expires: October 31, 2002
SECURITIES AND EXCHANGE COMMISSION --------------------------
WASHINGTON, D.C. 20549 Estimated average burden
hours per response 14.9
--------------------------
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. ___________)*
Sontra Medical Corporation
--------------------------------------------------------------------------------
(Name of Issuer)
Common
--------------------------------------------------------------------------------
(Title of Class of Securities)
00083568109
--------------------------------------------------------
(CUSIP Number)
04/30/04
--------------------------------------------------------------------------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
[ X ] Rule 13d-1(b)
[ ] Rule 13d-1(c)
[ ] Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which
would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or
otherwise subject to the liabilities of that section of the Act but shall be
subject to all other provisions of the Act (however, see the Notes).
CUSIP No. 00083568W109
-------------------------------------------------------------------------------
1. Names of Reporting Persons
I.R.S. Identification Nos. of above persons (entities only).
Hambrecht & Quist Capital Management LLC
01- 0628853
-------------------------------------------------------------------------------
2. Check the Appropriate Box if a Member of a Group (See Instructions)
(a)
(b) X
-------------------------------------------------------------------------------
3. SEC Use Only
-------------------------------------------------------------------------------
4. Citizenship or Place of Organization
Delaware
-------------------------------------------------------------------------------
Number of 5. Sole Voting Power
Shares 0
Beneficially
Owned by -----------------------------------------------------------------
Each 6. Shared Voting Power N/A
Reporting
Person With -----------------------------------------------------------------
7. Sole Dispositive Power N/A
-----------------------------------------------------------------
8. Shared Dispositive Power N/A
-------------------------------------------------------------------------------
9. Aggregate Amount Beneficially Owned by Each Reporting
Person 0
-------------------------------------------------------------------------------
10. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See
Instructions)
-------------------------------------------------------------------------------
11. Percent of Class Represented by Amount in Row (11) 0
-------------------------------------------------------------------------------
12. Type of Reporting Person (See Instructions)
IA
-------------------------------------------------------------------------------
SCHEDULE 13G EXHIBIT
ITEM 1.
Sontra Medical Corporation
10 Forge Parkway
Franklin, MA 02038
ITEM 2.
Hambrecht & Quist Capital Management LLC
30 Rowes Wharf - 4th Floor
Boston, MA 02110-3328
(Delaware corporation)
Common stock
CUSIP: 00083568W109
ITEM 3.
(e) Investment Adviser
ITEM 4.
Hambrecht & Quist Capital Management LLC ("HQCM") disclaims any
beneficial interest in the shares reported in this Schedule 13G.
Moreover, HQCM is of the view that the client accounts that it manages
are not acting as a "group" for purposes of Section 13(d) under the
Securities and Exchange Act of 1934 (the "1934 Act") and that it and
such clients are not otherwise required to attribute to each other the
"beneficial ownership" of securities "beneficially owned" under Rule
13d-3 promulgated under the 1934 Act. Therefore, HQCM is of the view
that the shares held in such accounts should not be aggregated for
purposes of Section 13(d). However, HQCM is making this filing on a
voluntary basis as if all the shares are beneficially owned by HQCM on a
joint basis.
0 shares of Common stock beneficially owned
0 of Common
0 sole voting power (i) and sole dispositive power (iii)
ITEM 5.
N/A
ITEM 6.
N/A
ITEM 7.
N/A
ITEM 8.
N/A
ITEM 9.
N/A
E-1
ITEM 10.
By signing below I certify that, to the best of my knowledge and belief,
the securities referred to above were acquired in the ordinary course of
business and were not acquired for the purpose of and do not have the
effect of changing or influencing the control of the issuer of such
securities and were not acquired in connection with or as a participant
in any transaction having such purposes or effect.
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true,
complete and correct.
Date: __5/14/04_____________________________________________
Signature: _______________________________________________
Name/Title: Kim Carroll, Vice President
Hambrecht & Quist Capital Management Incorporated
E-2